<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02917122</url>
  </required_header>
  <id_info>
    <org_study_id>A-BR-103-079</org_study_id>
    <nct_id>NCT02917122</nct_id>
  </id_info>
  <brief_title>The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease</brief_title>
  <acronym>Parkinson's</acronym>
  <official_title>The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson's disease (PD) is one of the most common neurological diseases manifested by&#xD;
      movement disturbance. The concomitant psychiatric symptoms, especially depression, are often&#xD;
      observed and have also great impact on patients' quality of life. The treatment of depressive&#xD;
      symptoms in PD with antidepressants as the majority remains variable and inefficient, which&#xD;
      complicates the disease prognosis. Transcranial direct current stimulation (tDCS) is a&#xD;
      non-invasive brain modulation technique and has been demonstrated to improve psychiatric&#xD;
      diseases such as major depression. In this study the investigators will assess the combined&#xD;
      effects of tDCS on sertraline for the treatment of depression in PD. Ten sessions of tDCS in&#xD;
      two weeks will be applied and the follow-up evaluation will continue bi-weekly for one month&#xD;
      after completing all sessions. The efficacy of tDCS vs sertraline will be compared and&#xD;
      evaluated with behavioral and cognitive outcome. In addition, the investigators will evaluate&#xD;
      if the baseline dopaminergic activity in brain could predict the treatment outcome by using&#xD;
      SPECT imaging. The investigators aim to establish the therapeutic parameters and safety&#xD;
      criteria of tDCS as an add-on or alternative therapy, and further enhance the overall&#xD;
      clinical efficacy in the treatment of depression in PD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design&#xD;
&#xD;
      This study is a factorial randomized, placebo-control trial, including 2 groups: 'sertraline&#xD;
      only' (sertraline + sham tDCS), and 'combined treatment' (sertraline + active tDCS). It is&#xD;
      planned to recruit 20 subjects for each group, which results in all together 40 participants.&#xD;
      Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions&#xD;
      for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after&#xD;
      the consecutive treatment. Both pharmacological and tDCS intervention will be started&#xD;
      simultaneously on the first day of the treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding is insufficient.&#xD;
  </why_stopped>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">August 2021</completion_date>
  <primary_completion_date type="Actual">August 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Modified-Unified Parkinson's Disease Rating Scale Among Different Weeks</measure>
    <time_frame>week 0 and 6</time_frame>
    <description>mds: modified-Unified Parkinson's Disease&#xD;
mds1 non-motor experiences of daily living: summed, 0-52 mds2 motor experiences of daily living: summed, 0-52 mds3 motor examination: summed, 0-132 mds4 motor complications: summed, 0-24&#xD;
higher value is worse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Hamilton Rating Scale for Depression Among Different Weeks</measure>
    <time_frame>week 0 and 6</time_frame>
    <description>Hamilton Rating Scale for Depression: summed, 0-50&#xD;
higher value is worse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Taiwanese Depression Questionnaire Among Different Weeks</measure>
    <time_frame>week 0 and 6</time_frame>
    <description>Taiwanese Depression Questionnaire: summed, 0-54&#xD;
higher value is worse</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>sertraline + sham tDCS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will take sham tDCS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sertraline + active tDCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>active tDCS</intervention_name>
    <description>Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.</description>
    <arm_group_label>sertraline + active tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Patients will take Sertraline.</description>
    <arm_group_label>sertraline + active tDCS</arm_group_label>
    <arm_group_label>sertraline + sham tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham tDCS</intervention_name>
    <description>Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.</description>
    <arm_group_label>sertraline + sham tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. In the opinion of the investigator, the participant is capable of understanding and&#xD;
             complying with protocol requirements.&#xD;
&#xD;
          2. The participant or, when applicable, the participant's legally acceptable&#xD;
             representative signs and dates a written, informed consent form and any required&#xD;
             privacy authorization prior to the initiation of any study procedures.&#xD;
&#xD;
          3. Suffers from Parkinson's disease fulfill the Parkinson's Disease Society Brain Bank&#xD;
             clinical criteria with insidious 2 or more PD symptoms (bradykinesia, tremor, or&#xD;
             rigidity).&#xD;
&#xD;
          4. Suffers from &quot;DSM-IV major depressive disorder, single episode&quot; or &quot;DSM-IV major&#xD;
             depressive disorder, recurrent&quot; according to Diagnostic &amp; Statistical Manual of Mental&#xD;
             Disorders, 4th Edition - Text Revision (DSM-IV-TR) criteria.&#xD;
&#xD;
          5. Reported duration of the current episode is ≥4 weeks and has not been treated with&#xD;
             antidepressants.&#xD;
&#xD;
          6. Has a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥20 at the&#xD;
             screening (baseline) visit.&#xD;
&#xD;
          7. Is a man or woman aged 18 to 75 years, inclusive.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Subjects known to have allergies to sertraline and pimozide.&#xD;
&#xD;
          2. Subjects showed any signs of substantial risk of suicide during the trial.&#xD;
&#xD;
          3. Subjects ever received electroconvulsive treatment.&#xD;
&#xD;
          4. Subjects co-morbid with other major mental disorders or with substance/alcohol&#xD;
             dependence or abuse in the past 6 months per DSM-IV criteria.&#xD;
&#xD;
          5. Nursing women, pregnant women or patients suspected pregnant.&#xD;
&#xD;
          6. History or presence of clinically significant hepatic, cardiovascular or renal&#xD;
             disease, or other serious medical disease that might compromise the study.&#xD;
&#xD;
          7. History of seizure disorder or need to taking medications that increase the risk of&#xD;
             seizure.&#xD;
&#xD;
          8. History or presence of dementia and any previous history of brain tumor, brain&#xD;
             arteriovenous malformation, encephalitis or meningitis.&#xD;
&#xD;
          9. Subjects ever received or plan to receive brain surgery during the trial.&#xD;
&#xD;
         10. Subjects with pacemaker or are contraindicated for MRI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kao Chin Chen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cheng-Kung University Hospital</affiliation>
  </overall_official>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <results_first_submitted>August 26, 2021</results_first_submitted>
  <results_first_submitted_qc>September 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2021</results_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cheng-Kung University Hospital</investigator_affiliation>
    <investigator_full_name>Kao Chin, Chen</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <keyword>Parkinson disease</keyword>
  <keyword>transcranial direct current stimulation</keyword>
  <keyword>depression</keyword>
  <keyword>dopamine transporter</keyword>
  <keyword>single photon emission computerized tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02917122/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sertraline + Sham tDCS</title>
          <description>Patients will take sham tDCS.&#xD;
Sertraline: Patients will take Sertraline.&#xD;
sham tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.</description>
        </group>
        <group group_id="P2">
          <title>Sertraline + Active tDCS</title>
          <description>Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.&#xD;
active tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.&#xD;
Sertraline: Patients will take Sertraline.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sertraline + Sham tDCS</title>
          <description>Patients will take sham tDCS.&#xD;
Sertraline: Patients will take Sertraline.&#xD;
sham tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.</description>
        </group>
        <group group_id="B2">
          <title>Sertraline + Active tDCS</title>
          <description>Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.&#xD;
active tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.&#xD;
Sertraline: Patients will take Sertraline.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.00" spread="8.50"/>
                    <measurement group_id="B2" value="61.86" spread="9.82"/>
                    <measurement group_id="B3" value="61.93" spread="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Modified-Unified Parkinson's Disease Rating Scale Among Different Weeks</title>
        <description>mds: modified-Unified Parkinson's Disease&#xD;
mds1 non-motor experiences of daily living: summed, 0-52 mds2 motor experiences of daily living: summed, 0-52 mds3 motor examination: summed, 0-132 mds4 motor complications: summed, 0-24&#xD;
higher value is worse</description>
        <time_frame>week 0 and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline + Sham tDCS</title>
            <description>Patients will take sham tDCS.&#xD;
Sertraline: Patients will take Sertraline.&#xD;
sham tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.</description>
          </group>
          <group group_id="O2">
            <title>Sertraline + Active tDCS</title>
            <description>Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.&#xD;
active tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.&#xD;
Sertraline: Patients will take Sertraline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Modified-Unified Parkinson's Disease Rating Scale Among Different Weeks</title>
          <description>mds: modified-Unified Parkinson's Disease&#xD;
mds1 non-motor experiences of daily living: summed, 0-52 mds2 motor experiences of daily living: summed, 0-52 mds3 motor examination: summed, 0-132 mds4 motor complications: summed, 0-24&#xD;
higher value is worse</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mds1 non-motor experiences of daily living-week0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" spread="5.48"/>
                    <measurement group_id="O2" value="10.00" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mds1 non-motor experiences of daily living-week6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.17" spread="3.43"/>
                    <measurement group_id="O2" value="8.25" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mds2 motor experiences of daily living-week0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" spread="3.50"/>
                    <measurement group_id="O2" value="2.25" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mds2 motor experiences of daily living-week6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="1.33"/>
                    <measurement group_id="O2" value="4.75" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mds3 motor examination-week0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.50" spread="12.93"/>
                    <measurement group_id="O2" value="18.75" spread="6.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mds3 motor examination-week6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.17" spread="10.34"/>
                    <measurement group_id="O2" value="19.50" spread="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mds4 motor complications-week0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="1.22"/>
                    <measurement group_id="O2" value="2.75" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mds4 motor complications-week6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="1.55"/>
                    <measurement group_id="O2" value="1.25" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change of Hamilton Rating Scale for Depression Among Different Weeks</title>
        <description>Hamilton Rating Scale for Depression: summed, 0-50&#xD;
higher value is worse</description>
        <time_frame>week 0 and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline + Sham tDCS</title>
            <description>Patients will take sham tDCS.&#xD;
Sertraline: Patients will take Sertraline.&#xD;
sham tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.</description>
          </group>
          <group group_id="O2">
            <title>Sertraline + Active tDCS</title>
            <description>Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.&#xD;
active tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.&#xD;
Sertraline: Patients will take Sertraline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Hamilton Rating Scale for Depression Among Different Weeks</title>
          <description>Hamilton Rating Scale for Depression: summed, 0-50&#xD;
higher value is worse</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.83" spread="4.79"/>
                    <measurement group_id="O2" value="27.40" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.83" spread="4.36"/>
                    <measurement group_id="O2" value="10.20" spread="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change of Taiwanese Depression Questionnaire Among Different Weeks</title>
        <description>Taiwanese Depression Questionnaire: summed, 0-54&#xD;
higher value is worse</description>
        <time_frame>week 0 and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline + Sham tDCS</title>
            <description>Patients will take sham tDCS.&#xD;
Sertraline: Patients will take Sertraline.&#xD;
sham tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.</description>
          </group>
          <group group_id="O2">
            <title>Sertraline + Active tDCS</title>
            <description>Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.&#xD;
active tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.&#xD;
Sertraline: Patients will take Sertraline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Taiwanese Depression Questionnaire Among Different Weeks</title>
          <description>Taiwanese Depression Questionnaire: summed, 0-54&#xD;
higher value is worse</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.50" spread="11.64"/>
                    <measurement group_id="O2" value="24.80" spread="11.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.83" spread="12.34"/>
                    <measurement group_id="O2" value="18.60" spread="16.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>week -1, 0, 2, 4, 6</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sertraline + Sham tDCS</title>
          <description>Patients will take sham tDCS.&#xD;
Sertraline: Patients will take Sertraline.&#xD;
sham tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.</description>
        </group>
        <group group_id="E2">
          <title>Sertraline + Active tDCS</title>
          <description>Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.&#xD;
active tDCS: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.&#xD;
Sertraline: Patients will take Sertraline.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kao Chin Chen</name_or_title>
      <organization>National Cheng Kung University</organization>
      <phone>+886-6-2353535 ext 5213</phone>
      <email>andchen@mail.ncku.edu.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

